Mp56-05 Renal Function Preservation in Ct1a Small Renal Masses Treated With Partial Nephrectomy vs. Microwave Ablation

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy IV (MP56)1 May 2024MP56-05 RENAL FUNCTION PRESERVATION IN CT1A SMALL RENAL MASSES TREATED WITH PARTIAL NEPHRECTOMY VS. MICROWAVE ABLATION Jessica X. Qiu, Aisha O. Kazeem, Laiba Murad, Priscilla Badu, Wendy Qi, Guofen Yan, Jennifer Lobo, and Noah Schenkman Jessica X. QiuJessica X. Qiu , Aisha O. KazeemAisha O. Kazeem , Laiba MuradLaiba Murad , Priscilla BaduPriscilla Badu , Wendy QiWendy Qi , Guofen YanGuofen Yan , Jennifer LoboJennifer Lobo , and Noah SchenkmanNoah Schenkman View All Author Informationhttps://doi.org/10.1097/01.JU.0001008940.44711.d4.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Microwave ablation (MWA) is an emerging therapy for cT1a small renal masses (SRM), especially for patients with significant co-morbidities. As oncological outcomes improve in ablative methods, renal function (RF) preservation is centrally important. Long term RF after MWA has not been clearly characterized with clinically relevant markers. We explored new methods for comparing RF outcomes for patients undergoing partial nephrectomy (PN) to MWA. METHODS: Our institutional database was retrospectively queried for patients with cT1a SRM treated with PN or MWA from 2005-21 with ≥2 years of RF data post-operatively, excluding those going 2 years without follow up. Kaplan Meier survival analysis was performed for local recurrence-free survival (LRFS) and RF decline. An event in RF decline was defined as either 30% eGFR decline or CKD stage progression persisting for ≥3 months. RESULTS: We included 120 patients, 49 treated with PN and 71 with MWA. MWA patients were older than PN patients (67 vs 53 years, p<0.001), with lower baseline eGFR (70.5 vs 90 mL/min/1.73 m2, p<0.001), and higher Charlson Comorbidity Index (CCI) (5 vs. 3, p<0.03) (Figure 1A). There was no significant difference in RF decline events (p=0.77, Figure 1B) or in LRFS (p=0.69). Further subgroup analyses were performed comparing RF decline in groups stratified by age, race, and baseline eGFR, still without significant difference between PN and MWA. CONCLUSIONS: Our data suggests MWA is comparable in long term RF preservation compared to PN, despite MWA patients being older, having more comorbidities, and having poorer baseline RF, while maintaining oncological efficacy. Interestingly in both PN and MWA, approximately half of the patients reached the RF endpoint. We were limited by a small patient cohort, but future studies with greater power could match for discrepant demographics to better compare RF outcomes. Download PPT Source of Funding: NIH R01 1R01CA284057-01 "Optimizing Treatment Decision Making for Patients with Localized Renal Mass" © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e927 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jessica X. Qiu More articles by this author Aisha O. Kazeem More articles by this author Laiba Murad More articles by this author Priscilla Badu More articles by this author Wendy Qi More articles by this author Guofen Yan More articles by this author Jennifer Lobo More articles by this author Noah Schenkman More articles by this author Expand All Advertisement PDF downloadLoading ...